KTTA vs. CANF, EFTR, PULM, CMMB, LIXT, TRVN, OBSV, CLVR, TENX, and ASLN
Should you be buying Pasithea Therapeutics stock or one of its competitors? The main competitors of Pasithea Therapeutics include Can-Fite BioPharma (CANF), eFFECTOR Therapeutics (EFTR), Pulmatrix (PULM), Chemomab Therapeutics (CMMB), Lixte Biotechnology (LIXT), Trevena (TRVN), ObsEva (OBSV), Clever Leaves (CLVR), Tenax Therapeutics (TENX), and ASLAN Pharmaceuticals (ASLN). These companies are all part of the "pharmaceutical preparations" industry.
Pasithea Therapeutics (NASDAQ:KTTA) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, community ranking, dividends, media sentiment and earnings.
Pasithea Therapeutics received 1 more outperform votes than Can-Fite BioPharma when rated by MarketBeat users. Likewise, 40.00% of users gave Pasithea Therapeutics an outperform vote while only 2.50% of users gave Can-Fite BioPharma an outperform vote.
Pasithea Therapeutics has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. Comparatively, Can-Fite BioPharma has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500.
Pasithea Therapeutics has a net margin of 0.00% compared to Can-Fite BioPharma's net margin of -1,027.46%. Pasithea Therapeutics' return on equity of -49.04% beat Can-Fite BioPharma's return on equity.
Can-Fite BioPharma has a consensus target price of $15.00, suggesting a potential upside of 673.20%. Given Can-Fite BioPharma's higher probable upside, analysts plainly believe Can-Fite BioPharma is more favorable than Pasithea Therapeutics.
Can-Fite BioPharma has higher revenue and earnings than Pasithea Therapeutics.
23.9% of Pasithea Therapeutics shares are owned by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are owned by institutional investors. 14.1% of Pasithea Therapeutics shares are owned by insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Pasithea Therapeutics had 1 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 2 mentions for Pasithea Therapeutics and 1 mentions for Can-Fite BioPharma. Pasithea Therapeutics' average media sentiment score of 0.67 beat Can-Fite BioPharma's score of 0.00 indicating that Pasithea Therapeutics is being referred to more favorably in the media.
Summary
Pasithea Therapeutics beats Can-Fite BioPharma on 10 of the 15 factors compared between the two stocks.
Get Pasithea Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KTTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KTTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pasithea Therapeutics Competitors List
Related Companies and Tools
